2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.06 Real-World Treatment Patterns and Outcomes of Tyrosine Kinase Inhibitors (TKI) in Anaplastic Lymphoma Kinase Positive (ALK+) Metastatic Non-Small Cell Lung Cancer (NSCLC)

PP01.06 Real-World Treatment Patterns and Outcomes of Tyrosine Kinase Inhibitors (TKI) in Anaplastic Lymphoma Kinase Positive (ALK+) Metastatic Non-Small Cell Lung Cancer (NSCLC)

Back to course

Pdf Summary

The document summarizes a research study on treatment patterns and outcomes of tyrosine kinase inhibitors (TKIs) in patients with anaplastic lymphoma kinase-positive (ALK) metastatic non-small cell lung cancer (NSCLC) treated with first-line (1L) monotherapy. Conducted as a retrospective observational analysis using Komodo Healthcare Map data from 2016-2023, the study aims to assess real-world outcomes such as Time to Treatment Discontinuation (TTD) and Overall Survival (OS) across several ALK-TKI treatments, including crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, and ensartinib.<br /><br />Key findings reveal that real-world outcomes for 1L brigatinib were similar to those for alectinib and lorlatinib, and more favorable than those for crizotinib. Despite a small sample size, the data support the effectiveness of brigatinib in the 1L setting. Patients with advanced ALK NSCLC reflected similar outcomes in both clinical trials and real-world settings.<br /><br />The study analyzed 1,476 patients, dividing them among the treatments: crizotinib, alectinib, brigatinib, and lorlatinib. Control data showed that better TTD and OS results were associated with alectinib and brigatinib over crizotinib, while lorlatinib showed better TTD, but not OS. However, statistical significance was not established when comparing brigatinib with alectinib or lorlatinib. Multivariable Cox proportional hazards models and propensity-score weighted hazard ratios were employed for comparative analysis, indicating no statistically significant differences across the TKIs.<br /><br />The research was funded by Takeda Development Center Americas, Inc., with acknowledgments for support in content development and analysis. Future research suggests a need for larger studies with an extended follow-up to better understand clinical treatment outcomes. The study was presented at the Targeted Therapies of Lung Cancer Meeting in February 2025.

Asset Subtitle

Rosalyn I. Marar

Keywords

tyrosine kinase inhibitors

anaplastic lymphoma kinase

metastatic non-small cell lung cancer

first-line monotherapy

real-world outcomes

brigatinib

alectinib

lorlatinib

crizotinib

Time to Treatment Discontinuation